Leora Horn, MD, MSc, FRCPC - The Present and Future of Immunotherapy as a Key Component of the Treatment Arsenal for Locally Advanced & Earlier Stages of Lung Cancer

1:06:36
 
Share
 

Manage episode 234972833 series 9912
By Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio streamed directly from their servers.
Go online to PeerView.com/DHV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Immune checkpoint inhibitor therapy is the new standard of care for patients with stage III, unresectable NSCLC who have not had disease progression after concurrent chemoradiotherapy. Immunotherapy-based treatment approaches are also being explored in multiple clinical trials in neoadjuvant and adjuvant settings in earlier stages of lung cancer. What is the rationale for and the evidence supporting the use of immunotherapy in locally advanced and early-stage lung cancer? How can we optimally integrate checkpoint inhibitors in the context of multimodal therapy? What factors and nuances should be taken into account when using immunotherapy in the management of patients with stage III NSCLC? In this activity, based on a recent live symposium held in San Diego, California, a panel of experts discusses the answers to these questions in the context of the latest evidence and provides practical guidance on how to transition immunotherapy into earlier stages of lung cancer in this MasterClass and Practicum. Upon completion of this activity, participants will be able to: Discuss the rationale for use, mechanisms of action, and role of immunotherapy in the management of lung cancer, Assess the latest data on the efficacy and safety of immunotherapy in stage III NSCLC, and the clinical implications of these data, Describe key trials assessing immune-based treatment approaches in locally advanced or earlier stages of lung cancer, Incorporate immunotherapy into treatment plans for patients with locally advanced or earlier stages of lung cancer, including in the context of clinical practice or clinical trials, based on the latest evidence, recommendations, and effective multidisciplinary collaboration and co-ordination of care.

267 episodes available. A new episode about every 0 hours averaging 55 mins duration .